Eli Lilly expects Medicare about-face on Alzheimer’s drugs coverage
By
Alicia Lasek
Apr 23, 2023
New data on Lilly’s experimental drug donanemab may influence CMS’s restrictive stance on coverage of this and other amyloid-busting Alzheimer’s treatments, a company executive says.
Feds expand Jardiance use to all heart failure patients
By
Alicia Lasek
Feb 25, 2022
Originally approved as a glucose control drug for patients with type 2 diabetes, Jardiance has more recently proven effective in reducing mortality and hospitalization in some heart failure patients.
FDA halts use of REGEN-COV, Eli Lilly monoclonal antibodies
By
Alicia Lasek
Jan 26, 2022
The Food and Drug Administration has revoked its emergency use authorizations for two monoclonal antibody cocktails that have served as COVID-19 treatment mainstays in long-term care facilities.
Clinical briefs for Thursday, Sept. 30
By
Alicia Lasek
Sep 30, 2021
Eli Lilly cuts its generic insulin price by another 40% for Medicare Part D, other beneficiaries … Federal district court judge upholds Ohio provider’s vaccine mandate … $33M awarded to determine...
Clinical briefs for Tuesday, Aug. 31
By
Alicia Lasek
Aug 31, 2021
NADONA announces 2021 Nurse Leader of the Year recipients … Eli Lilly’s COVID antibody treatment reauthorized in 20-plus states; restricted due to variants … Delta variant doubles risk of hospitalization...
Eli Lilly aims for dementia drug candidate’s approval in 2022; wants to ‘prioritize access’
By
Alicia Lasek
Aug 04, 2021
The Alzheimer’s disease-modifying drug donanemab is on track to be considered for full FDA approval by 2022, its developer said.
Bamlanivimab cuts risk of COVID in nursing homes and assisted living, study finds
By
Alicia Lasek
Jun 08, 2021
The investigation was conducted before the FDA revoked emergency use of the drug — a monoclonal antibody — due to the impact of genetic variants on efficacy. But it still can be used in combination...
HHS halts Eli Lilly’s single-drug COVID antibody treatment in U.S.; dual-drug alternative remains in...
By
Alicia Lasek
Mar 26, 2021
U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...
Feds halt an Eli Lilly antibody therapy in 3 states due to variant fears, while boosting the treatment...
By
Alicia Lasek
Mar 19, 2021
A COVID-19 variant circulating widely in California, Arizona and Nevada has rendered bamlanivimab alone ineffective, an FDA official reports. But Lilly says an approved alternative treatment “maintains...
Most COVID-19 antibody treatments given in assisted living, analysts find
By
Alicia Lasek
Feb 22, 2021
Fully 67% of monoclonal antibody treatments have been administered in assisted living communities. Health officials would like to encourage greater use.